Xellia Pharmaceuticals Seeks New Talent as it Expands Manufacturing Facility in Raleigh, NC

Xellia Pharmaceuticals Seeks New Talent as it Expands Manufacturing Facility in Raleigh, NC
Incentives from Wake County and City of Raleigh support significant increase in workforce
Copenhagen, Denmark and Raleigh, North Carolina – 15 September 2014 - Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, announces a range of new employment opportunities at its dedicated lyophilized (freeze-dried) vial manufacturing facility in Raleigh, North Carolina recently acquired from Fresenius Kabi.
Xellia is committed to increasing its team at the site by almost 50%, a decision that has been further supported by the award of two recent business incentives from Wake County and the City of Raleigh.
The manufacturing site is located close to the world famous Research Triangle Park and is Xellia's first facility in the US. Following the acquisition in July 2014, Xellia retained all 90 employees currently employed at the site and now plans to recruit more staff as it expands operations at the site further. The Company is looking to hire people across a wide spectrum of roles from manufacturing technicians and maintenance mechanics to senior quality control and assurance, validation and technology transfer specialists.
Carl-Åke Carlsson, CEO Xellia said: "We really appreciate the support we have received from Wake County and the City of Raleigh as we commit to expand our facility in Raleigh. The city's close proximity to world-renowned universities and a prominent cluster of leading pharma and biotech companies has made it an ideal base. Xellia's heritage and success is built on the quality and dedication of our staff and in Raleigh we aim to attract the most talented, productive employees and to enable them to grow and progress as the organization does."
David Vogt, Director, Plant Operations at the Raleigh Site and an employee of Fresenius Kabi prior to the acquisition said: "As an international, rapidly expanding group, Xellia has the combination of a committed long-term investor in Novo A/S which owns other companies with facilities in this area including Novo Nordisk and Novozymes, and a dynamic company culture of cooperation, innovation and openness. I feel very positive about the opportunities open to us and look forward to growing the team here further."
Xellia has over 100 years of pharmaceutical industry experience and specializes in difficult-to-manufacture and develop anti-infective products which are supplied to over 500 pharmaceutical companies in 70 countries around the world. The Company employs over 1,000 people and has R&D, manufacturing and commercial sites in eight countries.
Prospective employees can find out more about the range of roles and exciting opportunities available at Xellia's Raleigh site on the Careers page at www.xellia.com or by contacting [email protected]
- ENDS -
Notes To Editors
About Xellia
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, Hungary, USA and China, and currently employs over 1,000 people.
Xellia is a leading supplier of Vancomycin and Colistimethate Sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a  grant from the Research Council of Norway.
Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group
Further information about Xellia can be found at: www.xellia.com.
Further information about Novo A/S can be found at: www.novo.dk
About the Wake County Business Incentives Grant
Wake County approved a business incentive grant for Xellia Pharmaceuticals' manufacturing facility in Raleigh on 15 September 2014. The incentive, which provides Xellia with a cash grant equal to that awarded by the City of Raleigh is payable on an annual basis for five years. This performance-based grant requires that Xellia invests $100,000,000 in the site, and creates over 50 new jobs at 120% of the average County wage over the next five years.
About the City of Raleigh Business Incentives Grant
On the 2 September 2014 the City of Raleigh provided a business incentives grant to Xellia Pharmaceuticals for the expansion of its manufacturing facility located at 8900 Capital Boulevard. The grant is a performance based incentive and requires the company to create 40 permanent full-time jobs within the next five years and the retention of 90 existing jobs.
The grant also requires Xellia to make a minimal new property tax investment of $100,000,000. This grant will allocate 50 percent of paid property taxes to Xellia Pharmaceuticals on a yearly basis for five years.
Issued for and on behalf of Xellia by Instinctif Partners. 
For more information please contact:
Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00
David Vogt, Director, Plant Operations
Tel: +1 919 327 5647
Instinctif Partners (media relations)
Melanie Toyne Sewell / Eileen Paul / Jen Lewis
Tel: +44 (0) 20 7457 2029 / +44 (0)1260 296 500